Ambroxol Hydrochloride/Levodropropizine

盐酸氨溴索/左羟丙哌嗪

Report date: 2024/01/19 15:04:05

Base Information

Drug NameAmbroxol Hydrochloride/Levodropropizine
Drug Alias Name左羟丙哌嗪/盐酸氨溴索Ambroxol/levodropropizineLevodropropizine/ambroxolAmbroxol HCl/levodropropizineLevodropropizine/ambroxol HCl +[6] 
ClassificationSmall molecules
Mechanisms of ActionSodium channel alpha subunit modulatorsNeuropeptides modulators
TargetsSodium channel alpha subunitNeuropeptides
Therapy Area/IndicationsCough
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes Ambroxol HydrochlorideLevodropropizine
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHanmi Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsCough

Other Information

ATC CodeN/A
Related LinksN/A